Pharmaceutical patent owners may have been concerned to read some of the key features of South Africa’s new IP policy. Recently adopted by the country’s cabinet, it seeks to clamp down on perceived “evergreening” by life sciences companies – raising the prospect of changes to patentability criteria – and suggests an increased role for compulsory licensing.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

IAM is the only publication that places a business focus on intellectual property. Readers are given real insight into, and guidance on, managing intellectual property as a true business asset.

Marc Kaufman
Partner
Reed Smith LLP

Benefits

Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?